DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
The generic ingredient in TIVICAY PD is dolutegravir sodium. There are seventeen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the dolutegravir sodium profile page.
Generic Entry Opportunity Date for 213983
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 213983
Suppliers and Packaging for NDA: 213983
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||TABLET, FOR SUSPENSION;ORAL||Strength||EQ 5MG BASE|
|Approval Date:||Jun 12, 2020||TE:||RLD:||Yes|
|Patent:||Start Trial||Patent Expiration:||Oct 5, 2027||Product Flag?||Y||Substance Flag?||Y||Delist Request?|
|Patent:||Start Trial||Patent Expiration:||Dec 8, 2029||Product Flag?||Y||Substance Flag?||Y||Delist Request?|
Complete Access Available with Subscription